cxcl10

Artemotil (SM-227) 是一种新型的速效抗疟药，可研究耐Plasmodium falciparum 的恶性疟原虫疟疾，IC50值为 1.61 nM。

NI-0801 (Anti-CXCL10 IP-1) 是 CHO 表达的人源化靶向 CXCL10 IP-10 的单克隆抗体，可用于研究白癜风和胆汁性肝硬化。

AMG 487 是可口服的选择性趋化因子受体3拮抗剂，对 I-IP-10、I-ITAC 和 MIG 的 IC50 值分别为 8、15 和 36nM。

GW 9508 是一种选择性 G 蛋白偶联受体FFA1(GPR40) 和GPR120激动剂。它是一种葡萄糖敏感性胰岛素促分泌剂和 ATP 敏感性钾通道开放剂，具有抗炎和抗动脉粥样硬化活性。

Astin C（Asterin）是一种可以从Aster tataricus中提取的天然环肽，能够特异性地阻断IRF3在STING信号体上的募集抑制cGAS-STING信号和由细胞质dna触发的先天炎症反应，导致小鼠更容易感染HSV-1，显著减弱自身炎症反应。

Adenosine-2'-monophosphate (2'-AMP) 是由 2’,3'-CAMP 转化的核苷，抑制小胶质细胞产生炎性细胞因子，通过 A2A 受体抑制活化的原代小鼠小胶质细胞产生 TNF-α 和 CXCL10。

PF-1367550，作为一种泛JAK抑制剂，能有效降低原发性气道上皮细胞中CXCL9、CXCL10 和 CXCL11 的释放水平。

PD-L1 HDAC-IN-1 (Compound 14) 是一种PD-L1和HDAC的抑制剂，可以阻碍PD-1 PD-L1相互作用以及HDAC2和HDAC3的活性，其IC50值分别为88.10、27.98和14.47 nM。在MCF-7细胞中，该化合物显示轻微细胞毒性（IC50=19.34 μM）。PD-L1 HDAC-IN-1 通过上调PD-L1和CXCL10的表达，促进 T 细胞向 TME 的浸润，从而增强抗肿瘤免疫反应。

GHN105 是一种具有口服活性的STING抑制剂，能够在THP-1人单核细胞中以IC50为4.4 μM的浓度抑制STING依赖性的IFN-β分泌。GHN105 可降低小鼠血清中的IFN-β、IL-6和CXCL10水平，并在DSS诱发的急性结肠炎小鼠模型中缓解结肠炎。该化合物在小鼠体内展示了良好的药代动力学参数，口服生物利用度为43%，半衰期为1.1小时。

β-Defensin-2 is a peptide with antimicrobial properties that protects the skin and mucosal membranes of the respiratory, genitourinary, and gastrointestinal tracts.1It inhibits the growth of periodontopathogenic and cariogenic bacteria, includingP. gingivalisandS. salivarius.2β-Defensin-2 (30 μg/ml) stimulates gene expression and production of IL-6, IL-10, CXCL10, CCL2, MIP-3α, and RANTES by keratinocytes.3It also stimulates calcium mobilization, migration, and proliferation of keratinocytes when used at concentrations of 30, 10, and 40 μg/ml, respectively. β-Defensin-2 induces IL-31 production by human peripheral blood-derived mast cellsin vitrowhen used at a concentration of 10 μg/ml and by rat mast cellsin vivofollowing a 500 ng intradermal dose.4Expression of β-defensin-2 is increased in psoriatic skin and chronic wounds.5,6 1.Lehrer, R.I.Primate defensinsNat. Rev. Microbiol.2(9)727-738(2004) 2.Ouhara, K., Komatsuzawa, H., Yamada, S., et al.Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL37, produced by human epithelial cellsJ. Antimicrob. Chemother.55(6)888-896(2005) 3.Niyonsaba, F., Ushio, H., Nakano, N., et al.Antimicrobial peptides human β-defensins stimulate epidermal keratinocyte migration, proliferation and production of proinflammatory cytokines and chemokinesJ. Invest. Dermatol.127(3)594-604(2007) 4.Niyonsaba, F., Ushio, H., Hara, M., et al.Antimicrobial peptides human β-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cellsJ. Immunol.184(7)3526-3534(2010) 5.Huh, W.-K., Oono, T., Shirafuji, Y., et al.Dynamic alteration of human β-defensin 2 localization from cytoplasm to intercellular space in psoriatic skinJ. Mol. Med. (Berl.)80(10)678-684(2002) 6.Butmarc, J., Yufit, T., Carson, P., et al.Human β-defensin-2 expression is increased in chronic woundsWound Repair Regen.12(4)439-443(2004)

β-Defensin-3 is a peptide with antimicrobial properties that protects the skin and mucosal membranes of the respiratory, genitourinary, and gastrointestinal tracts. It inhibits the growth of the periodontopathogenic and cariogenic bacteria F. nucleatum, S. mutans, S. sobrinus, S. salivarius, and L. casei (MICs = 12.5-100 mg/l). It also inhibits the growth of S. aureus, S. pyogenes, P. aeruginosa, E. coli, and C. albicans. β-Defensin-3 stimulates gene expression and production of IL-6, IL-10, CXCL10, CCL2, MIP-3α, and RANTES by keratinocytes when used at a concentration of 30 μg/ml. It also stimulates calcium mobilization, migration, and proliferation of keratinocytes when used at concentrations of 30, 5, and 20 μg/ml, respectively. β-Defensin-3 induces IL-31 production by human peripheral blood-derived mast cells in vitro when used at a concentration of 10 μg/ml and by rat mast cells in vivo following a 500 ng intradermal dose.

β-Defensin-4 is a peptide with antimicrobial properties that protects the skin and mucosal membranes of the respiratory, genitourinary, and gastrointestinal tracts. It induces migration of monocytes in vitro when used at a concentration of 10 nM but does not affect migration of neutrophils and eosinophils. β-Defensin-4 (30 μg/ml) stimulates gene expression and production of IL-6, IL-10, CXCL10, CCL2, MIP-3α, and RANTES by keratinocytes. It also stimulates calcium mobilization, migration, and proliferation of keratinocytes when used at concentrations of 30, 10, and 40 μg/ml, respectively. β-Defensin-4 induces IL-31 production by human peripheral blood-derived mast cells in vitro when used at a concentration of 10 μg/ml and by rat mast cells in vivo following a 500 ng intradermal dose. It also inhibits growth of E. coli, P. aeruginosa, and S. aureus with lethal concentration (LC) values of 5, 12, and 15 μM, respectively, of S. carnosus (MIC = 4.5 μg/ml), and of C. albicans with a minimum fungicidal concentration (MFC) value of 7.5 μM.

CAY10748 is an agonist of stimulator of interferon genes (STING; IC50= 0.3794 μM in a competition binding assay).1It activates STING in STING-expressing, but not STING knockout, THP-1 cells (EC50s = 0.287 and >100 μM, respectively, in a reporter assay). It induces phosphorylation of STING at the serine in position 366, as well as phosphorylation of TBK1 and IFN regulatory factor 3 (IRF3), indicating activation of the STING-TBK1-IRF3 signaling pathway. CAY10748 increases the secretion of IFN-β and the levels of chemokine (C-X-C motif) ligand 10 (CXCL10), and IL-6 in peripheral blood mononuclear cells (PBMCs) when used at a concentration of 10 μM. It also reduces tumor growth in a CT26 murine colon cancer model when administered at a dose of 0.15, but not 1.5, mg/kg. 1.Xi, Q., Wang, M., Jia, W., et al.Design, synthesis, and biological evaluation of amidobenzimidazole derivatives as stimulator of interferon genes (STING) receptor agonistsJ. Med. Chem.63(1)260-282(2019)

STING agonist 1a is an agonist of stimulator of interferon genes (STING).1It induces expression of an IRF-inducible SEAP reporter gene in a cell-based assay (EC50= 16.77 μM). STING agonist 1a (12.5-100 μM) induces expression of IFN-β, IL-6, and chemokine (C-X-C motif) ligand 10 (CXCL10) in THP-1 cells, an effect that can be reversed by STING knockout or the STING inhibitor H-151 . 1.Hou, H., Yang, R., Liu, X., et al.Discovery of triazoloquinoxaline as novel STING agonists via structure-based virtual screeningBioorg. Chem.100103958(2020)

Rosolic Acid是Nrf2及其下游靶点的激活剂，能够提升血管生成因子的水平，并降低TNF-α和IL-1β等炎症标志物以及CXCL10和CCL2等凋亡标志物的水平。同时，Rosolic Acid能够恢复胰腺细胞功能，并对受到内质网应激影响的内皮细胞(EC)提供保护。

TBK1-IN-1 是一种具有特异性和高效性的 TANK 结合激酶 1 (TBK1) 抑制剂（IC50: 22.4 nM），具有抗癌活性。TBK1-IN-1 对 TBK1 下游靶基因 cxcl10 和 ifnβ 的表达有抑制作用。

Eldelumab (BMS-936557) 是一种人源化抗 IP-10 IgG 1型单克隆抗体，对 CXCL10 具有抑制作用。Eldelumab 具有抗炎活性，可与 CXCL10 结合，可用于研究类风湿性关节炎。

STING激动剂12L是一种刺激干扰素基因(STING)的激动剂。它与野生型STING结合(IC50 = 1.15 µM)，以及STING的R232、AQ和Q变体(IC50分别为1.06、0.61和1.12 µM)，并在THP-1和RAW 264.7细胞中诱导报告基因表达(EC50分别为0.38和12.94 µM)。STING激动剂12L (5 µM)在THP-1细胞中诱导IFNB1、CXCL10和IL6 mRNA的表达。在体内，STING激动剂12L (10 mg/kg)提高了血浆IFN-β水平，并且在B16/F10小鼠黑色素瘤模型中减少了肿瘤体积和肺转移灶的数量。

STING激动剂D61（D61）是干扰素基因刺激剂(STING)的激动剂。它在基于细胞的分析中诱导IFN3诱导的分泌性碱性磷酸酶(SEAP)报告基因和IFN-β诱导的报告基因的表达（EC50分别为52.9和116 nM）。D61（4, 6, 和8 µM）增加了编码IFN-β和化学因子（C-X-C基序）配体10（CXCL10）的mRNA的表达以及TANK结合激酶1（TBK1）、IRF3和STING在THP-1单核细胞中的磷酸化。在体内，D61（每隔一天0.25 mg/kg）在CT26小鼠结肠癌模型中减少肿瘤体积，而不影响体重。

COB-187 作为一种高效的 ATP 竞争性选定性 GSK-3β 抑制剂，通过可逆的、依赖半胱氨酸 (Cys)-199 的机制，能够抑制 GSK-3。此外，COB-187 能抑制由 LPS 引起的细胞因子生成，以及 SARS-CoV-2 刺突蛋白引发的 CXCL10 生成。

TLR2 6 agonist (also a putative TLR10 ligand). Activates NF-κB. Induces pro-inflammatory cytokines including IL-8, IL-1β, CCL20 and TNF-α in vitro. Synergizes with IFNγ to induce CXCL10 release from melanoma cells.